Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time

Claudio Liguori, Fabio Placidi, Francesca Izzi, Marzia Nuccetelli, Sergio Bernardini, Maria Giovanna Sarpa, Fabrizio Cum, Maria Grazia Marciani, Nicola Biagio Mercuri, Andrea Romigi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: The aim od this study is to test whether metabolism of beta-amyloid and tau proteins changes in narcolepsy along with the disease course. Methods: We analyzed a population of narcoleptic drug-naïve patients compared to a sample of healthy controls. Patients and controls underwent lumbar puncture for assessment of cerebrospinal fluid (CSF) beta-amyloid1–42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) levels. Moreover, based on the median disease duration of the whole narcolepsy group, the patients were divided into two subgroups: patients with a short disease duration (SdN, 5 years). Results: We found significantly lower CSF Aβ42 levels in the whole narcolepsy group with respect to controls. Taking into account the patient subgroups, we documented reduced CSF Aβ42 levels in SdN compared to both LdN and controls. Even LdN patients showed lower CSF Aβ42 levels with respect to controls. Moreover, we documented higher CSF p-tau levels in LdN patients compared to both SdN and controls. Finally, a significant positive correlation between CSF Aβ42 levels and disease duration was evident. Conclusions: We hypothesize that beta-amyloid metabolism and cascade may be impaired in narcolepsy not only at the onset but also along with the disease course, although they show a compensatory profile over time. Concurrently, also CSF biomarkers indicative of neural structure (p-tau) appear to be altered in narcolepsy patients with a long disease duration. However, the mechanism underlying beta-amyloid and tau metabolism impairment in narcolepsy remains still unclear and deserves to be better elucidated.

Original languageEnglish
Pages (from-to)277-283
Number of pages7
JournalSleep and Breathing
Volume20
Issue number1
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Narcolepsy
Amyloid
Cerebrospinal Fluid
tau Proteins
Spinal Puncture
Amyloid beta-Peptides
Biomarkers

Keywords

  • Beta-amyloid
  • CSF
  • Narcolepsy
  • Orexin
  • Tau protein

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Clinical Neurology

Cite this

Liguori, C., Placidi, F., Izzi, F., Nuccetelli, M., Bernardini, S., Sarpa, M. G., ... Romigi, A. (2016). Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time. Sleep and Breathing, 20(1), 277-283. https://doi.org/10.1007/s11325-015-1305-9

Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time. / Liguori, Claudio; Placidi, Fabio; Izzi, Francesca; Nuccetelli, Marzia; Bernardini, Sergio; Sarpa, Maria Giovanna; Cum, Fabrizio; Marciani, Maria Grazia; Mercuri, Nicola Biagio; Romigi, Andrea.

In: Sleep and Breathing, Vol. 20, No. 1, 01.03.2016, p. 277-283.

Research output: Contribution to journalArticle

Liguori, C, Placidi, F, Izzi, F, Nuccetelli, M, Bernardini, S, Sarpa, MG, Cum, F, Marciani, MG, Mercuri, NB & Romigi, A 2016, 'Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time', Sleep and Breathing, vol. 20, no. 1, pp. 277-283. https://doi.org/10.1007/s11325-015-1305-9
Liguori C, Placidi F, Izzi F, Nuccetelli M, Bernardini S, Sarpa MG et al. Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time. Sleep and Breathing. 2016 Mar 1;20(1):277-283. https://doi.org/10.1007/s11325-015-1305-9
Liguori, Claudio ; Placidi, Fabio ; Izzi, Francesca ; Nuccetelli, Marzia ; Bernardini, Sergio ; Sarpa, Maria Giovanna ; Cum, Fabrizio ; Marciani, Maria Grazia ; Mercuri, Nicola Biagio ; Romigi, Andrea. / Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time. In: Sleep and Breathing. 2016 ; Vol. 20, No. 1. pp. 277-283.
@article{e0699c22ca52474f91b0be71e79edd61,
title = "Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time",
abstract = "Purpose: The aim od this study is to test whether metabolism of beta-amyloid and tau proteins changes in narcolepsy along with the disease course. Methods: We analyzed a population of narcoleptic drug-na{\"i}ve patients compared to a sample of healthy controls. Patients and controls underwent lumbar puncture for assessment of cerebrospinal fluid (CSF) beta-amyloid1–42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) levels. Moreover, based on the median disease duration of the whole narcolepsy group, the patients were divided into two subgroups: patients with a short disease duration (SdN, 5 years). Results: We found significantly lower CSF Aβ42 levels in the whole narcolepsy group with respect to controls. Taking into account the patient subgroups, we documented reduced CSF Aβ42 levels in SdN compared to both LdN and controls. Even LdN patients showed lower CSF Aβ42 levels with respect to controls. Moreover, we documented higher CSF p-tau levels in LdN patients compared to both SdN and controls. Finally, a significant positive correlation between CSF Aβ42 levels and disease duration was evident. Conclusions: We hypothesize that beta-amyloid metabolism and cascade may be impaired in narcolepsy not only at the onset but also along with the disease course, although they show a compensatory profile over time. Concurrently, also CSF biomarkers indicative of neural structure (p-tau) appear to be altered in narcolepsy patients with a long disease duration. However, the mechanism underlying beta-amyloid and tau metabolism impairment in narcolepsy remains still unclear and deserves to be better elucidated.",
keywords = "Beta-amyloid, CSF, Narcolepsy, Orexin, Tau protein",
author = "Claudio Liguori and Fabio Placidi and Francesca Izzi and Marzia Nuccetelli and Sergio Bernardini and Sarpa, {Maria Giovanna} and Fabrizio Cum and Marciani, {Maria Grazia} and Mercuri, {Nicola Biagio} and Andrea Romigi",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s11325-015-1305-9",
language = "English",
volume = "20",
pages = "277--283",
journal = "Sleep and Breathing",
issn = "1520-9512",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time

AU - Liguori, Claudio

AU - Placidi, Fabio

AU - Izzi, Francesca

AU - Nuccetelli, Marzia

AU - Bernardini, Sergio

AU - Sarpa, Maria Giovanna

AU - Cum, Fabrizio

AU - Marciani, Maria Grazia

AU - Mercuri, Nicola Biagio

AU - Romigi, Andrea

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Purpose: The aim od this study is to test whether metabolism of beta-amyloid and tau proteins changes in narcolepsy along with the disease course. Methods: We analyzed a population of narcoleptic drug-naïve patients compared to a sample of healthy controls. Patients and controls underwent lumbar puncture for assessment of cerebrospinal fluid (CSF) beta-amyloid1–42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) levels. Moreover, based on the median disease duration of the whole narcolepsy group, the patients were divided into two subgroups: patients with a short disease duration (SdN, 5 years). Results: We found significantly lower CSF Aβ42 levels in the whole narcolepsy group with respect to controls. Taking into account the patient subgroups, we documented reduced CSF Aβ42 levels in SdN compared to both LdN and controls. Even LdN patients showed lower CSF Aβ42 levels with respect to controls. Moreover, we documented higher CSF p-tau levels in LdN patients compared to both SdN and controls. Finally, a significant positive correlation between CSF Aβ42 levels and disease duration was evident. Conclusions: We hypothesize that beta-amyloid metabolism and cascade may be impaired in narcolepsy not only at the onset but also along with the disease course, although they show a compensatory profile over time. Concurrently, also CSF biomarkers indicative of neural structure (p-tau) appear to be altered in narcolepsy patients with a long disease duration. However, the mechanism underlying beta-amyloid and tau metabolism impairment in narcolepsy remains still unclear and deserves to be better elucidated.

AB - Purpose: The aim od this study is to test whether metabolism of beta-amyloid and tau proteins changes in narcolepsy along with the disease course. Methods: We analyzed a population of narcoleptic drug-naïve patients compared to a sample of healthy controls. Patients and controls underwent lumbar puncture for assessment of cerebrospinal fluid (CSF) beta-amyloid1–42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) levels. Moreover, based on the median disease duration of the whole narcolepsy group, the patients were divided into two subgroups: patients with a short disease duration (SdN, 5 years). Results: We found significantly lower CSF Aβ42 levels in the whole narcolepsy group with respect to controls. Taking into account the patient subgroups, we documented reduced CSF Aβ42 levels in SdN compared to both LdN and controls. Even LdN patients showed lower CSF Aβ42 levels with respect to controls. Moreover, we documented higher CSF p-tau levels in LdN patients compared to both SdN and controls. Finally, a significant positive correlation between CSF Aβ42 levels and disease duration was evident. Conclusions: We hypothesize that beta-amyloid metabolism and cascade may be impaired in narcolepsy not only at the onset but also along with the disease course, although they show a compensatory profile over time. Concurrently, also CSF biomarkers indicative of neural structure (p-tau) appear to be altered in narcolepsy patients with a long disease duration. However, the mechanism underlying beta-amyloid and tau metabolism impairment in narcolepsy remains still unclear and deserves to be better elucidated.

KW - Beta-amyloid

KW - CSF

KW - Narcolepsy

KW - Orexin

KW - Tau protein

UR - http://www.scopus.com/inward/record.url?scp=84961167157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961167157&partnerID=8YFLogxK

U2 - 10.1007/s11325-015-1305-9

DO - 10.1007/s11325-015-1305-9

M3 - Article

AN - SCOPUS:84961167157

VL - 20

SP - 277

EP - 283

JO - Sleep and Breathing

JF - Sleep and Breathing

SN - 1520-9512

IS - 1

ER -